Presentation on theme: "Financial Conflict of Interest and Medical Research"— Presentation transcript:
1Financial Conflict of Interest and Medical Research Stephen R. Marder, M.D.
2Disclosure Information for Stephen R. Marder, MD Advisory boardAbbott; Amgen; Roche; Shire; Otsuka America Pharmaceutical, Inc.; Wyeth; Pfizer,Research SupportNovartis; Glaxo Smith Kline; Sunovion; Psychogenics
3OverviewMore than ever, there is an incentive for academic researchers to work with industryNIH is not equipped to develop drugs and bring them to marketIndustry researchers seldom translate the newest biological findings into new pharmacological approachesEthical Concerns have led many to mistrust research emerging from industry
4Research Budget (billions): Top 5 Pharmaceutical Companies
5Drug Development’s Major Challenge: Improving Technical Success Candidate SelectionPhase I First Human Dose100%100%80%1 yearPhase II1 ½ yearsFirst Efficacy Dose50%55%Phase III2 yearsFirst Registration DoseSubmission20%10%3 yearsLaunch11%2001 CMR Data9%1 year12 1/24 1/28 1/2Development time - years
6DefinitionA conflict of interest is a set of circumstances that creates a risk that professional judgment or actions regarding a primary interest will be unduly influenced by a secondary interest.Institute of Medicine Report, 2009
7Cases example 1Nancy Fern Olivieri is a hematologist from Toronto who participated in multi-site study of a drug for thalassaemia.She became concerned about toxicity of the drug and a lack of efficacy. She informed the ethics board of the hospital and the company. The board instructed her to notify study participants.The company informed her that her confidentiality agreement prevented from notifying subjects. She did anyway.
8Case example 2A prominent psychiatrist-researcher wrote a review in a very prominent journal that focused on new experimental approaches to treating depression.It turned out that the author had significant COI’s for some of the approaches. These were not disclosed in the article.
10Is there evidence of bias in research? Research funded by industry is more likely to report positive findings (Sismondo, 2008)Examination of comparisons of antipsychotics found the funder’s drug superior 90% of the time. (Heres, 2006)Sponsors can control when and where results are published.R
16Appelbaum and GoldDescribe the Principal-Agent Problem where the physician or investigator is engaged as an agent of the drug company.Other principals may be the scientific community, research subjects, the patients who may benefit from study results
17Approaches Disclosure of Financial conflicts Management of conflicts Eliminating conflicts
18Approaches to Disclosure The 2010 Affordable Care and Patient Protection Act contains sweeping sunshine provisions including the development of a searchable public Web site that will list payments from drug, device, biological, and medical products companies to physicians by name.
19Limitations of Disclosure Unclear if readers pay attentionThe details of the conflict are not reportedSeldom included in abstractsPeople can never be trusted to be unbiased. The mind doesn’t work like that
20“And thou shalt take no bribe; for a bribe blinds the eye of the wise; and perverts the words of the righteous”
22Gold and AppelbaumRaba stated: What is the reason for [the prohibition against taking] a gift? Because as soon as a man receives a gift from another he becomes so well disposed towards him that [the other person] becomes like his own person, and no man sees himself in the wrong.
25Managing Investigator COI AAMC recommends that researchers with financial interests related to study results should not participate or should give up the interests.
26IOM RecommendationAcademic medical centers and other research institutions should establish a policy that individuals generally may not conduct research with human participants if they have a significant financial interest in an existing or potential product or a company that could be affected by the outcome of the research.
27IOM Recommendation (cont) Exceptions to the policy should be made public and should be permitted only if the conflict of interest committee (a) determines that an individual’s participation is essential for the conduct of the research and (b) establishes an effective mechanism for managing the conflict and protecting the integrity of the research.
28SummaryConcerns about the public’s confidence in medical research should be taken seriouslyVital components of a study design, data analysis, and interpretation should be reviewed by individuals who are unconflicted.Academic scientists should have all agreements with industry reviewed by their institutions to assure that a company does not infringe on the timely publication of all information.